格隆汇个股放量排行榜 | 9月17日
格隆汇勾股大数据显示，上一交易日梁志天设计集团(02262)、恒宇集团(02448)、龙辉国际控股(01007)、安宁控股(00128)、康特隆(01912)、富智康集团(02038)、宝新金融(01282)、中国公共采购(01094)、广泽国际发展(00989)、新城悦服务(01755)、桐成控股(01611)、METROPOLIS CAP(08621)、中国香精香料(03318)、勒泰集团(00112)、IGG(00799)、爱德新能源(02623)、亚信科技(01675)、苍南仪表(01743)、数字王国(00547)、达利食品(03799)、兑吧(01753)、达力集团(00029)、力世纪(00860)、高鑫零售(06808)、盛业资本(08469)、同佳健康(00286)、伯明翰体育(02309)、豆盟科技(01917)、恒益控股(01894)、万咖壹联(01762)、新城市建设发展(00456)、港大零售(01255)、高山企业(00616)、新城发展控股(01030)、雄岸科技(01647)、新秀丽(01910)、大禹金融(01073)、前进控股集团(01499)、中汇集团(00382)、比速科技(01372)、钱唐控股(01466)、慕容控股(01575)、中国铝业(02600)、丽新发展(00488)、普拉达(01913)、首沣控股(01703)、中国农产品交易(00149)、酷派集团(02369)、彩客化学(01986)、中国北大荒(00039)、奥星生命科技(06118)、铁货(01029)、美联集团(01200)、王朝酒业(00828)、北京体育文化(01803)出现放量，量比分别为2.24、2.10、2.08、1.68、1.66、1.59、1.56、1.50、1.47、1.38、1.35、1.31、1.29、1.28、1.22、1.18、1.15、1.12、1.07、1.04、1.02、0.99、0.99、0.98、0.95、0.93、0.91、0.90、0.88、0.84、0.83、0.82、0.75、0.70、0.68、0.62、0.58、0.55、0.53、0.50、0.47、0.46、0.45、0.43、0.42、0.34、0.34、0.33、0.31、0.30、0.26、0.26、0.24、0.16、0.14。
股票名称 成交额（万） 量比 持续放量天数 梁志天设计集团(02262)2823.952.246恒宇集团(02448)319.822.102龙辉国际控股(01007)1443.502.081安宁控股(00128)1012.231.681康特隆(01912)2220.181.662富智康集团(02038)15578.841.593宝新金融(01282)762.711.561中国公共采购(01094)228.531.503广泽国际发展(00989)1824.031.471新城悦服务(01755)4140.751.386桐成控股(01611)3523.791.351METROPOLIS CAP(08621)187.091.311中国香精香料(03318)128.111.292勒泰集团(00112)170.511.283IGG(00799)6582.641.223爱德新能源(02623)102.041.182亚信科技(01675)502.361.151苍南仪表(01743)147.831.125数字王国(00547)212.741.071达利食品(03799)4262.611.043兑吧(01753)534.901.022达力集团(00029)1220.770.992力世纪(00860)397.920.995高鑫零售(06808)5293.600.983盛业资本(08469)950.370.951同佳健康(00286)492.500.932伯明翰体育(02309)440.990.913豆盟科技(01917)194.910.901恒益控股(01894)691.810.881万咖壹联(01762)1161.290.843新城市建设发展(00456)113.470.833港大零售(01255)392.710.821高山企业(00616)106.370.751新城发展控股(01030)9810.100.702雄岸科技(01647)1128.230.682新秀丽(01910)7610.750.622大禹金融(01073)563.400.582前进控股集团(01499)353.030.551中汇集团(00382)1501.810.532比速科技(01372)111.650.501钱唐控股(01466)5022.220.472慕容控股(01575)146.750.461中国铝业(02600)4485.820.456丽新发展(00488)131.370.432普拉达(01913)1380.530.422首沣控股(01703)366.640.343中国农产品交易(00149)164.010.343酷派集团(02369)1132.550.332彩客化学(01986)374.600.313中国北大荒(00039)360.270.302奥星生命科技(06118)157.360.262铁货(01029)123.600.262美联集团(01200)365.580.242王朝酒业(00828)246.590.162北京体育文化(01803)415.120.144
备注：以上数据由格隆汇数据中心根据港交所数据加工计算所得，并不保证100%精确。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
